A Study of HER2-Targeted Antibody-Drug Conjugates Compared With Hormone-Based Therapy for Hormone Receptor-Positive, HER2-Low Metastatic Breast Cancer
A Phase 3 Randomized Controlled Clinical Study of Anti-HER2 Antibody-Drug Conjugates for Hormone Receptor-Positive/HER2-Low Metastatic Breast Cancer (the Rosy Trial)
This phase 3 study will compare anti-HER2 antibody-drug conjugate treatment with hormone-receptor-directed treatment in women with endocrine therapy-resistant, hormone receptor-positive, HER2-low metastatic breast cancer. Participants are assigned at random in a 1:1 ratio to one of the two treatment groups. The primary objective is to compare progression-free survival. Other planned assessments include overall survival, tumor response, adverse events, and patient-reported quality-of-life and psychological measures. The planned sample size is 288 participants, subject to confirmation against the final approved protocol.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Ying Wang
- 전화번호: +86 13925038181
- 이메일: wangy556@mail.sysu.edu.cn
연구 장소
-
-
Guangdong
-
Guangzhou, Guangdong, 중국
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adult female, age 18-70 years, with metastatic breast cancer confirmed by pathology or imaging. **The consent form states 18-75 years; confirm the approved age range.**
- Hormone receptor-positive disease (ER ≥1% and/or PR ≥1%) and HER2-low disease (IHC 1+, or IHC 2+ with no amplification by FISH/ISH).
- Prior endocrine therapy failure.
- At least one evaluable target lesion under RECIST 1.1, or osteolytic bone metastases only.
- Stable or asymptomatic brain metastases permitted.
- ECOG performance status ≤2 and life expectancy ≥3 months.
- Prior treatment-related toxicities resolved to CTCAE v5.0 grade ≤1, except alopecia or other toxicity judged safe by the investigator.
- Adequate marrow, hepatic, renal, and cardiac function as specified in the final protocol; the application lists WBC ≥3.0×10^9/L, ANC ≥1.5×10^9/L, platelets ≥70×10^9/L, total bilirubin ≤3×ULN, ALT/AST ≤2.5×ULN (≤5×ULN with liver metastases), serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min, LVEF ≥55%, and QTcF ≤470 ms.
- Able to understand study procedures, provide informed consent, and sign the consent form.
Exclusion Criteria:
- Patients who had received chemotherapy, radiotherapy, immunotherapy, and endocrine therapy for breast cancer within 2 weeks before enrollment.;
- Patients who had performed major surgery within 2 weeks before enrollment.
- Severe heart disease or discomfort within 12 months, including, but not limited to, the following: unstable angina pectoris, myocardial infarction, cerebral hemorrhage and cerebral infarction (except for silent lacunar cerebral infarction without treatment);
- Have active autoimmune diseases (such as corticosteroids or immunosuppressive drugs) requiring systemic treatment in the past 2 years, excluding those with adrenal insufficiency requiring corticosteroid replacement therapy;
- Have a clear history of neurological or mental disorders, including epilepsy or dementia;
- According to the judgment of the researchers, there are some accompanying diseases that seriously endanger the safety of patients or affect patients to complete the study.
- Those who have been known to have allergic history to all study drugs or similar agentss;
- According to the estimation of the investigator , the patient's compliance with the clinical study is insufficient or the researcher believes that there are other factors that are not suitable for the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Anti-HER2 antibody-drug conjugate treatment.
Participants receive one of the anti-HER2 antibody-drug conjugates (ADCs) permitted by the protocol: DS-8201 and A1811. The assigned ADC is administered according to the approved protocol until objective disease progression, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. |
Administered once every 21 days (q21d). Add the protocol-approved dose, route, and treatment duration/stop rule. Administered once every 21 days (q21d). Add the protocol-approved dose, route, and treatment duration/stop rule. |
|
활성 비교기: Hormone-receptor-directed treatment (endocrine therapy with or without targeted therapy).
Participants receive endocrine therapy alone or in combination with a targeted therapy, according to the approved protocol. |
Doctors choose endocrine therapy independently |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS)
기간: 24 months
|
Time from randomization to first documented disease progression or death from any cause. |
24 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival (OS)
기간: 36 months
|
Time from randomization to death from any cause. |
36 months
|
|
Objective Response Rate (ORR)
기간: 12 months
|
Proportion of evaluable participants whose best overall response is complete or partial response per RECIST 1.1. |
12 months
|
|
Disease Control Rate (DCR)
기간: 12 months
|
Proportion with complete response, partial response, or stable disease per the approved definition. |
12 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Adverse events
기간: From the first dose of study treatment to 30 days after the last dose of study treatment.
|
The incidence of adverse events in the two groups will be analyzed and graded according to NCI CTCAE version 5.0. |
From the first dose of study treatment to 30 days after the last dose of study treatment.
|
공동 작업자 및 조사자
스폰서
스폰서
간행물 및 유용한 링크
일반 간행물
- Koleva-Kolarova RG, Oktora MP, Robijn AL, Greuter MJW, Reyners AKL, Buskens E, de Bock GH. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2017 Apr;55:16-25. doi: 10.1016/j.ctrv.2017.01.001. Epub 2017 Feb 20.
- Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, Andrade S, Batel-Marques F. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review. Breast Cancer Res. 2015 Nov 17;17:140. doi: 10.1186/s13058-015-0648-2.
- Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018 Jul 10;36(20):2105-2122. doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30.
- Giuliani S, Ciniselli CM, Leonardi E, Polla E, Decarli N, Luchini C, Cantaloni C, Gasperetti F, Cazzolli D, Berlanda G, Bernardi D, Pellegrini M, Triolo R, Ferro A, Verderio P, Barbareschi M. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases. Virchows Arch. 2016 Jul;469(1):45-50. doi: 10.1007/s00428-016-1940-y. Epub 2016 Apr 21.
- Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med. 2014 Feb;138(2):213-9. doi: 10.5858/arpa.2012-0617-OA. Epub 2013 Oct 28.
- Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14.
- Yao X, Jiang J, Wang X, Huang C, Li D, Xie K, Xu Q, Li H, Li Z, Lou L, Fang J. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat. 2015 Aug;153(1):123-33. doi: 10.1007/s10549-015-3503-3. Epub 2015 Aug 8.
- Ocana A, Amir E, Pandiella A. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. Breast Cancer Res. 2020 Jan 31;22(1):15. doi: 10.1186/s13058-020-1252-7.
- Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, Chen C, Strout P, Mulgrew K, McGlinchey K, Fleming R, Bezabeh B, Meekin J, Stewart D, Kennedy M, Martin P, Buchanan A, Dimasi N, Michelotti E, Hollingsworth R. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Res. 2017 May 15;77(10):2686-2698. doi: 10.1158/0008-5472.CAN-16-2854. Epub 2017 Mar 10.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- SYSKY-2022-208-07
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .